FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366315195> ?p ?o ?g. }

• W4366315195 endingPage "18" @default.
• W4366315195 startingPage "12" @default.
• W4366315195 abstract "Background: The ideal combination regimen for Helicobacter pylori (HP) eradication has not yet been determined and the success rate of HP eradication has been extensively reduced worldwide due to increasing antibiotic resistance. So this multinational multi-center randomized controlled trial was designed to evaluate the efficacy of tetracycline +levofloxacin for HP eradication. Methods: During a 6-month period, all of the cases with HP infection in eight referral tertiary centers of three countries were included and randomly allocated to receive either tetracycline + levofloxacin or clarithromycin plus amoxicillin quadruple regimen for two weeks. For all of the participants, pantoprazole was continued for 4 more weeks and after one to two weeks of off-therapy, they underwent urea breath test C13 to prove eradication. Results: Overall 788 patients were included (358 male (45.4%), average age 44.2 years). They were diagnosed as having non-ulcer dyspepsia (516 cases, 65.5%), peptic ulcer disease (PUD) (234 cases, 29.69%), and intestinal metaplasia (38 cases, 4.8%). Racially 63.1% were Caucasian, 14.5% Arab, 15.6% African, and 6.1% Asian. The participants were randomly allocated to groups A and B to receive either tetracycline + levofloxacin or clarithromycin. Among groups A and B in intention to treat (ITT) and per protocol (PP) analysis, 75.2% & 82.1% (285 cases) and 67.5% & 70.1% (276 cases) of participants achieved eradication, respectively (P = 0.0001). The complete compliance rate in groups A and B were 84.4% and 83.6%, respectively. During the study, 33.5% of the participants in group A (127 cases) reported side effects while the complication rate among group B was 27.9% (114 cases, P = 0.041). The most common complaints among groups A and B were nausea and vomiting (12.6% & 9.3%) and abdominal pain (4.48% & 2.68%), respectively. The rate of severe complications that caused discontinuation of medication in groups A and B were 2.1% and 1.46%, respectively (P = 679). In subgroup analysis, the eradication rates of tetracycline+levofloxacin among patients with non-ulcer dyspepsia, PUD, and intestinal metaplasia were 79.4%, 88.1%, and 73.9%, respectively. These figures in group B (clarithromycin base) were 71.3%, 67.6%, and 61.5% respectively (P = 0.0001, 0.0001, and 0.043). Conclusion: Overall, the combination of tetracycline+levofloxacin is more efficient for HP eradication in comparison with clarithromycin+amoxicillin despite more complication rate. In areas with a high rate of resistance to clarithromycin, this therapeutic regimen could be an ideal choice for HP eradication, especially among those who were diagnosed with PUD." @default.
• W4366315195 created "2023-04-20" @default.
• W4366315195 creator A5003450004 @default.
• W4366315195 creator A5006880184 @default.
• W4366315195 creator A5014438057 @default.
• W4366315195 creator A5015618682 @default.
• W4366315195 creator A5019565749 @default.
• W4366315195 creator A5022996190 @default.
• W4366315195 creator A5023618329 @default.
• W4366315195 creator A5026170434 @default.
• W4366315195 creator A5032462545 @default.
• W4366315195 creator A5033225610 @default.
• W4366315195 creator A5039306791 @default.
• W4366315195 creator A5040319275 @default.
• W4366315195 creator A5051950026 @default.
• W4366315195 creator A5059928947 @default.
• W4366315195 creator A5072080401 @default.
• W4366315195 creator A5077058925 @default.
• W4366315195 creator A5077857769 @default.
• W4366315195 creator A5081957303 @default.
• W4366315195 creator A5085278966 @default.
• W4366315195 creator A5088876410 @default.
• W4366315195 date "2023-01-30" @default.
• W4366315195 modified "2023-10-18" @default.
• W4366315195 title "Levofloxacin+Tetracycline Quadruple Regimen for Eradication of <i>Helicobacter pylori</i>: A Multicenter Multinational Randomized Controlled Trial" @default.
• W4366315195 cites W1797829304 @default.
• W4366315195 cites W1809766612 @default.
• W4366315195 cites W1969980017 @default.
• W4366315195 cites W1981058900 @default.
• W4366315195 cites W1992605662 @default.
• W4366315195 cites W1997711745 @default.
• W4366315195 cites W2005473353 @default.
• W4366315195 cites W2007139524 @default.
• W4366315195 cites W2012160272 @default.
• W4366315195 cites W2042045508 @default.
• W4366315195 cites W2044906864 @default.
• W4366315195 cites W2053060021 @default.
• W4366315195 cites W2060399464 @default.
• W4366315195 cites W2066784126 @default.
• W4366315195 cites W2073719339 @default.
• W4366315195 cites W2091242636 @default.
• W4366315195 cites W2153165213 @default.
• W4366315195 cites W2158986090 @default.
• W4366315195 cites W2163680402 @default.
• W4366315195 cites W2165252044 @default.
• W4366315195 cites W2168147536 @default.
• W4366315195 cites W2412040979 @default.
• W4366315195 cites W2436835668 @default.
• W4366315195 cites W2464958356 @default.
• W4366315195 cites W2472193147 @default.
• W4366315195 cites W2527848138 @default.
• W4366315195 cites W2588772815 @default.
• W4366315195 cites W2596197199 @default.
• W4366315195 cites W2738483237 @default.
• W4366315195 cites W2766138567 @default.
• W4366315195 cites W2847560921 @default.
• W4366315195 cites W2875993675 @default.
• W4366315195 cites W2881320234 @default.
• W4366315195 cites W2884430948 @default.
• W4366315195 cites W2893380085 @default.
• W4366315195 cites W2908062341 @default.
• W4366315195 cites W2913418201 @default.
• W4366315195 cites W2954336462 @default.
• W4366315195 cites W2973002586 @default.
• W4366315195 cites W2981603079 @default.
• W4366315195 cites W2989717957 @default.
• W4366315195 cites W2996368257 @default.
• W4366315195 cites W3003026598 @default.
• W4366315195 cites W3008085218 @default.
• W4366315195 cites W3020838715 @default.
• W4366315195 cites W3024537506 @default.
• W4366315195 cites W3028064081 @default.
• W4366315195 cites W3036461262 @default.
• W4366315195 cites W3043766162 @default.
• W4366315195 cites W3047046052 @default.
• W4366315195 cites W3080196903 @default.
• W4366315195 cites W3081995893 @default.
• W4366315195 cites W3121580126 @default.
• W4366315195 cites W3133870136 @default.
• W4366315195 doi "https://doi.org/10.34172/mejdd.2023.314" @default.
• W4366315195 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37547163" @default.
• W4366315195 hasPublicationYear "2023" @default.
• W4366315195 type Work @default.
• W4366315195 citedByCount "0" @default.
• W4366315195 crossrefType "journal-article" @default.
• W4366315195 hasAuthorship W4366315195A5003450004 @default.
• W4366315195 hasAuthorship W4366315195A5006880184 @default.
• W4366315195 hasAuthorship W4366315195A5014438057 @default.
• W4366315195 hasAuthorship W4366315195A5015618682 @default.
• W4366315195 hasAuthorship W4366315195A5019565749 @default.
• W4366315195 hasAuthorship W4366315195A5022996190 @default.
• W4366315195 hasAuthorship W4366315195A5023618329 @default.
• W4366315195 hasAuthorship W4366315195A5026170434 @default.
• W4366315195 hasAuthorship W4366315195A5032462545 @default.
• W4366315195 hasAuthorship W4366315195A5033225610 @default.
• W4366315195 hasAuthorship W4366315195A5039306791 @default.
• W4366315195 hasAuthorship W4366315195A5040319275 @default.
• W4366315195 hasAuthorship W4366315195A5051950026 @default.

• next